Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SR-878 in Rheumatoid Arthritis
NCT07433335Phase 1Recruiting
- Sponsor
- SciRhom GmbH
- Start
- Apr 2026
- Primary completion
- Feb 2028
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of SR-878 in rheumatoid arthritis (RA), sponsored by SciRhom GmbH. Primary endpoints: Treatment-Emergent Adverse Events, Dose-Limiting Toxicities and 1 more. Started Apr 2026; status: recruiting.
02
Drugs
SR-878
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT07433335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07433335.